T. Asai et al. / Phytochemistry 82 (2012) 149–157
155
mixture of hydrocarbons) and six pools (I–VI) according to the TLC
profile: Pool I (70 mg, frs. 18–20, a mixture of 1, 2 and 3, eluted
with hexane–EtOAc, 1:1), Pool II (159 mg, a mixture of 4 and 5,
frs. 21–22, eluted with hexane–EtOAc, 1:2), Pool III/IV (222 mg,
frs. 23–27, eluted with hexane–EtOAc, 1:2), Pool V (54 mg, a mix-
ture of 11 and 12, frs. 28–33, eluted with EtOAc-MeOH, 5:1) and
Pool VI (22 mg, a mixture of 13 and 14, frs. 34–36, eluted with
EtOAc–MeOH, 5:1 ? 3:1). The Pool III/IV was further separated
by silica gel CC with increasing polarity of hexane-EtOAc to give
Pool III (195 mg, a mixture of 6, 7 and 8, eluted with hexane–EtOAc,
1:2) and Pool IV (23 mg, a mixture of 9 and 10, eluted with EtOAc).
A portion of Pool I (26 mg) was further separated by HPLC (MeOH–
H2O, 20:1; flow rate, 1.0 mL/min) to afford 1 (6.8 mg), 2 (11.1 mg)
and 3 (6.8 mg) at 12.4, 12.8 and 13.3 min, respectively. A portion of
Pool II (10 mg) was further separated by HPLC (MeOH–H2O, 20:1;
flow rate, 1.0 mL/min) to afford 4 (7.8 mg) and 5 (1.7 mg) at 13.9
and 14.7 min, respectively. A portion of Pool III (18 mg) was further
separated by HPLC (MeOH–H2O, 20:1; flow rate, 1.0 mL/min, UV
detection at 215 nm) to afford 6 (3.6 mg), 7 (6.0 mg) and 8
(4.4 mg) at 12.4, 12.8and 13.4 min, respectively.
PTLC (hexane–EtOAc, 3:1) gave the peracetyl derivative 1a
(2.5 mg): Colorless oil; ½a D25
ꢂ
– 1.0 (c = 0.22, CHCl3); IR (CHCl3) mmax
2930, 2860, 1720 cm–1; (+)-HRFABMS m/z: 649.3950 [M+Na]+
(calcd for C34H58O10Na, 649.3928); 1H NMR d: 0.88 (t, J = 6.9 Hz,
H3-22), 1.52-1.20 (m), 1.63 (m, Ha-3), 1.75 (m, Hb-3), 2.00 (s, Ac),
2.02 (s, Ac), 2.03 (s, Ac), 2.32 (ddd, J = 11.7, 9.4, 4.5 Hz, Ha-2),
2.43 (ddd, J = 11.7, 8.0, 4.5 Hz, Hb-2), 3.56 (m, H-11), 3.69 (m, H-
50), 4.09 (dd, J = 12.3, 4.6 Hz, Ha-60), 4.15 (dd, J = 12.3, 1.9 Hz, Hb-
60), 4.53 (d, J = 8.0 Hz, H-10), 4.98 (dd, J = 9.7, 8.0 Hz, H-20), 5.10 (t,
J = 9.7 Hz, H-40), 5.20 (t, J = 9.7 Hz, H-30), 13C NMR d: 14.11, 20.63,
20.65, 20.68, 22.68, 24.33, 24.35, 25.09, 26.88, 27.29, 27.52,
27.64, 28.14, 29.34, 29.61, 29.65 (x2), 29.68, 29.93, 31.90, 34.12,
34.44, 34.60, 62.22, 68.28, 71.46, 71.77, 73.14, 80.85, 100.34,
169.28, 169.31, 170.43, 173.94.
4.5. Glomeraside B (2)
Colorless oil; (+)-HRFABMS m/z: 543.3919 [M+H]+ (calcd for
C30H55O8, 543.3897); ½a D25
ꢂ
– 6.3 (c = 1.1, CHCl3); IR (CHCl3) mmax
3590, 3440, 2930, 2860, 1720 cm–1; for 1H and 13C NMR spectro-
scopic data, see Tables 1 and 2, respectively.
A portion of Pool IV (12 mg) in Et2O (100
l
L) and MeOH (40
lL)
was treated with TMSCH2N2 in hexane (0.6 M solution, 40
l
L) at
Methyl 10(R)-hydroxydocosanoate 16 (0.8 mg) was obtained
from 2 (2.0 mg) in the same manner as described for 1. EIMS m/z:
352 ([M–H2O]+, 1), 339 ([M–MeO]+, 2), 320 ([M–H2O–MeO]+, 10),
201 (C-10/C-11 cleavage, 53), 172 (46), 169 (201–MeOH) (100),
143 (14), 87 (42), 55 (24); 1H NMR (CDCl3) d: 3.67 (s, OMe), 3.59
(m, H-10), 2.30 (t, J = 7.6 Hz, H2-2), 1.65-1.25 (m), 0.88 (t,
J = 6.7 Hz, H3-22). A portion of 16 (0.1 mg) was converted into
the corresponding TMS ether in the same manner as that described
for 15 and was analyzed by GLC and EIMS. EIMS of the TMS deriv-
ative of 16: m/z 427 ([M–Me]+, 9), 411 ([M–MeO]+, 10), 395 (28),
287 (C-11/C-12 cleavage, 100), 257 (C-10/C-11 cleavage, 100),
129 (31), 73 (65), 57 (36).
room temperature for 30 min. Removal of the solvent by flushing
with N2, followed by purification by silica gel CC (eluted with hex-
ane–EtOAc 2:1), yielded a mixture of methyl esters 9m and 10m
(11 mg). A portion of Pool V (10 mg) was similarly converted to a
mixture of methyl esters 11m and 12m (9.0 mg). A portion of Pool
VI (14 mg) was dissolved in EtOAc (200 lL) and ethereal CH2N2
was added until a yellow color persisted. Removal of the solvent
by flushing with N2 followed by purification by silica gel CC (eluted
with hexane–EtOAc 1:1) yielded a mixture of methyl esters 13m
and 14m (11 mg). An aliquot (10 mg) of these was separated by
HPLC (MeOH–H2O, 20:1; flow rate, 1.0 mL/min) to afford 9m
(7.4 mg) and 10m (1.8 mg) at 13.4 and 14.0 min, respectively.
The mixture of the methyl esters 11m and 12m (17 mg) was sep-
arated by HPLC (MeOH–H2O, 20:1; flow rate, 1.0 mL/min) to afford
11m (12 mg) and 12m (1.8 mg) at 15.3 and 15.9 min, respectively.
The mixture of the methyl esters 13m and 14m (10 mg) was sep-
arated by HPLC (MeOH–H2O, 20:1; flow rate, 1.0 mL/min) to afford
13m (5.7 mg) and 14m (2.0 mg) at 11.8 and 12.3 min, respectively.
Compound 2 (2.2 mg) was converted to the corresponding ace-
tate 2a (2.4 mg) following the procedure described for compound
1: Colorless oil; ½a D25
ꢂ
– 5.0 (c = 0.24, CHCl3); IR (CHCl3) mmax 2930,
2860, 1720 cm–1; (+)-HRFABMS m/z: 649.3906 [M+Na]+ (calcd for
C
34H58O10Na, 649.3928); 1H NMR (CDCl3) d: 0.88 (t, J = 6.9 Hz,
H3-22), 1.49-1.20 (m), 1.65 (m, Ha-3), 1.71 (m, Hb-3), 2.01 (s, Ac),
2.03 (s, Ac (x2)), 2.37 (m), 3.58 (m, H-10), 3.69 (m, H-50), 3.97 (dd,
J = 12.1, 5.5 Hz, Ha-60), 4.23 (dd, J = 12.1, 1.9 Hz, Hb-60), 4.57 (d,
J = 8.0 Hz, H-10), 4.98 (dd, J = 9.7, 8.0 Hz, H-20), 5.07 (t, J = 9.7 Hz,
H-40), 5.21 (t, J = 9.7 Hz, H-30); 13C NMR d:14.13, 20.66 (x2),
20.70, 22.69, 23.66, 24.37, 25.05, 26.21, 26.59, 27.00, 27.09,
29.36, 29.65, 29.67 (x3), 29.71, 29.90, 31.92, 33.82, 34.01, 34.36,
62.28, 68.59, 71.26, 71.83, 73.18, 80.20, 100.24, 169.30, 169.37,
170.45, 173.91.
4.4. Glomeraside A (1)
Colorless oil; (+)-HRFABMS m/z: 543.3894 [M+H]+ (calcd for
C
30H55O8, 543.3897); ½a D25
ꢀ 9.2 (c = 0.60, CHCl3); IR (CHCl3) mmax
ꢂ
3590, 3440, 2930, 2860, 1720 cm–1; for 1H and 13C NMR spectro-
scopic data, see Tables 1 and 2, respectively.
Compound 1 (3.0 mg) was hydrolyzed as described in our pre-
vious paper (Asai and Fujimoto, 2010) to give glucose and a hydro-
xy-fatty acid. Glucose was identified by TLC and GC–MS as
described in our previous paper (Asai and Fujimoto, 2010; Asai
et al., 2009). Treatment of the hydroxy-fatty acid with ethereal
CH2N2 gave, after PTLC purification (hexane–EtOAc, 6:1), methyl
11(R)-hydroxydocosanoate 15 (1.3 mg). Amorphous; EIMS m/z:
352 ([M–H2O]+, 1), 339 ([M–MeO]+, 2), 320 ([M–H2O–MeO]+, 10),
215 (C-11/C-12 cleavage, 42), 186 (45), 183 (215–MeOH, 42), 143
(23), 87 (42); 1H NMR (CDCl3) d: 3.67 (s, OMe), 3.59 (m, H-11),
2.30 (t, J = 7.6 Hz, H2-2), 1.65-1.25 (m), 0.88 (t, J = 7.8 Hz, H3-22).
A portion of 15 was converted to the corresponding TMS ether
as described previously (Asai and Fujimoto, 2010) and analyzed
by GLC and EIMS. EIMS of TMS derivative of 15: m/z 427 ([M–
Me]+, 9), 411 ([M–MeO]+, 10), 395 (28), 287 (C-11/C-12 cleavage,
100), 257 (C-10/C-11 cleavage, 100), 129 (31), 73 (65), 57 (36).
4.6. Glomeraside C (3)
Colorless oil; (+)-HRFABMS m/z: 543.3807 [M+H]+ (calcd for
C
30H55O8, 543.3897); ½a D25
ꢂ
0 (c = 0.68, CHCl3); IR (CHCl3) mmax
3590, 3440, 2930, 2860, 1720 cm–1; for 1H and 13C NMR spectro-
scopic data, see Tables 1 and 2, respectively.
Methyl 9(R)-hydroxydocosanoate 17 (0.8 mg) was obtained
from 3 (2.0 mg) in the same manner as that described for 1. 17:
EIMS m/z: 352 ([M–H2O]+, 1), 339 ([M–MeO]+, 2), 320 ([M–H2O–
MeO]+, 10), 187 (C-9/C-10 cleavage, 45), 158 (45), 155 (188–MeOH,
100), 87 (30), 55 (20); 1H NMR (CDCl3) d: 3.67 (s, OMe), 3.59 (m, H-
9), 2.30 (t, J = 7.6 Hz, H2-2), 1.65-1.25 (m), 0.88 (t, J = 7.8 Hz, H3-22).
A portion of the methyl ester 17 was converted to the correspond-
ing TMS ether in the same manner as described for 15 and ana-
lyzed by GLC and EIMS. EIMS of the TMS derivative of 17: m/z
427 ([M–Me]+, 9), 411 ([M–MeO]+, 12), 395 (12), 285 (C-8/C-9
cleavage, 100), 259 (C-9/C-10 cleavage, 100), 129 (28), 73 (55),
57 (53).
Compound 1 (2.2 mg) was treated with Ac2O (20
dine (40 L) at room temperature overnight. Removal of the sol-
vent by flushing with N2 and purification of the crude product by
lL) and pyri-
l